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ABSTRACT  
In diabetic patients with foot infection, osteomyelitis shows up in 20% of cases 
and highly increase the probability to require a lower-extremity amputation. 
Unfortunately, there are no agreed guidelines for its diagnosis and early diagnosis 
is necessary to ensure appropriate treatment. Nevertheless, it may take several 
weeks for bone infection to produce defects on x-ray and bone biopsy may 
occasionally be misleading. MRI is the gold standard diagnostic technique for 
osteomyelitis (OM) but because of its low availability other noninvasive and 
reliable diagnostic markers are studied; within these, C reactive protein (CRP) is 
the principal; the levels of this protein rise highly in response of an infection. In 
this thesis, an initial comprehensive literature search is carried out on topics 
related to acute phase reactants, diabetic foot infection and diagnosis of OM. 
Medical records of 30 patients with bone infection who attended Medical 
Emergency from Diabetic Foot Unit during a period of 1,5 years are searched and 
studied. The aim of this study is to compare statistically serum levels of CRP to 
see if it is an OM indicator; moreover, to know if there is another factor, besides 
this mentioned, which is also altered. Finally, the validity of CRP is shown to have 
diagnostic value front of an OM.  
 
Keywords: diabetic foot, osteomyelitis, C reactive protein, amputation, acute 
phase reactants  
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RESUM  
L’osteomielitis està present en un 20% dels casos d’infecció del peu en persones 
diabètiques i augmenta la probabilitat de requerir una amputació de les 
extremitats inferiors. Desafortunadament, no hi ha pautes acordades pel seu 
diagnòstic. Un diagnòstic exacte és necessari per garantir un tractament 
adeqüat. No obstant, la infecció òssia pot tardar diverses setmanes en produir 
defectes en una radiografia simple i la biopsia òssia pot ser enganyosa. La RM 
és l’estàndard d’or per a la osteomielitis (OM) però, a causa de la seva baixa 
disponibilitat, altres marcardors diagnòstics no invasius i confiables han sigut 
estudiats. Dins d’aquests, la proteïna C reactiva (PCR) és la principal; els nivells 
d’aquesta s’eleven altament en presència d’infecció. En aquest treball, es du a 
terme inicialment una recerca bibliogràfica completa sobre temes relacionats 
amb reactants de fase aguda, infecció del peu diabètic i diagnòstic de la OM. Es 
busquen les històries clíniques de 30 pacients de la Unitat de Peu Diabètic amb 
infecció òssia que van assistir a Urgències en un període comprès entre el 
setembre de 2013 i l’abril de 2015. Seguidament, es du a terme un estudi dels 
anàlisis sanguinis dels pacients. L’objectiu d’aquest estudi és comparar els 
nivells sèrics de PCR per veure si és un indicador de l’OM; tanmateix, saber si hi 
ha un altre factor, apart de l’esmentat anteriorment, que també s’alteri. A 
continuació, les dades són analitzades estadísticament. Finalment, la validesa 
de la PCR es demostra que té un valor diagnòstic davant una OM.   
 
Paraules clau: peu diabètic, osteomielitis, proteïna C reactiva, amputació, 
reactants de fase aguda   
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1. INTRODUCTION  
Diabetic foot ulcers cause significant morbidity and are responsible of a large 
number of hospitalizations. It has been reported that approximately 20% of 
diabetic patients develop foot ulcers at some point in their lives. However, other 
studies indicate that between 50% and 95% of cases of amputations of lower 
extremities due to non-traumatic issues correspond to diabetic patients1. Around 
40% of diabetic patients who have been amputated require subsequent 
amputation in the next five years from the initial event, reporting morbidity of 50% 
in the first three years2. 
Many studies have shown that diabetic patients have immune and tissue repair 
disorders, such as leukocyte and platelet dysfunction, basal membrane thinning 
and atherosclerosis of small vessels, abnormalities in the function of neutrophils 
and fibroblasts, peripheral neuropathy and tissue hypoxia which interact with 
each other in the genesis of the diabetic foot. Ischemia contributes a 30-40% in 
the formation of ulcers3. 
In most cases, the main determinant in the decision to carry out an amputation in 
diabetic foot is the presence of osteomyelitis. This, which involves bone infection 
both cortical and bone marrow, is a serious and common problem in diabetic 
patients because it is precisely a consequence of diabetes complications, 
especially neuropathy and, to a lesser degree, the vasculopathy, the 
immunological and healing defects.  
However, the diagnosis of osteomyelitis in this group of patients still remains a 
challenge. The classic signs and symptoms of infection may be absent or masked 
by coexisting vascular disease or neuropathy. In patients with suspected 
osteomyelitis, the radiography is the initial study. However, radiographic changes 
may take two weeks to appear. The gold standard for diagnosis of osteomyelitis 
is bone biopsy. Yet, this invasive procedure is not always practical in patients with 
severe peripheral vascular disease and diabetes, that’s the reason why 
noninvasive and reliable markers are looked for4. 
Magnetic resonance imaging (MRI) has been recognized for early diagnosis with 
a sensitivity between 77-100% and a specificity of 79 to 100% according to 
different series of studies3-5. The disadvantages of this study are: its high cost, 
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low availability and the decreasing of specificity in cases of previous surgery, 
neuropathic osteoarthropathy (Charcot) and other inflammatory diseases such as 
rheumatoid arthritis. 
During the acute phase of inflammation around 50 glycoproteins can be identified 
as reactants. For many years, the erythrocyte sedimentation rate (ESR) has been 
used as an acute phase reactant and marker of inflammation. ESR is an indirect 
way of measuring concentrations of plasma proteins of acute inflammation 
(though many of the physicochemical factors that affect ESR are unknown). 
In osteomyelitis, acute or chronic, ESR is usually high and decreases front of a 
favorable response to treatment, thus has been considered as a useful marker 
for the diagnosis and monitoring of diabetic foot.  
Moreover, C-reactive protein (CRP) is another marker of acute inflammation. An 
increase in serum concentrations of this peptide has been observed during 
inflammation and tissue necrosis. Generally, the CRP values reflect the severity 
of inflammation or tissue injury; rises few hours after the acute process had begun 
and is normalized within few days after treatment6. 
The aim of this research is to compare serum levels of CRP in patients with 
diabetic foot and, at the same time, see how others parameters of blood analysis 
are modified in the presence of osteomyelitis.  
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2. DIABETIC FOOT SYNDROME  
The diabetic foot syndrome is considered by the World Health Organization 
(WHO) as: the presence of ulceration, infection and/or gangrene of the foot 
associated with diabetic neuropathy and various degrees of peripheral vascular 
disease, result from the complex interaction of various factors induced by a 
maintained hyperglycemia. 
The risk of ulceration and amputation in diabetic patients is much higher 
compared to non-diabetic patients: the risk of a diabetic patient of developing 
diabetic foot ulcers is greater than 25% and it is estimated that every 30 seconds 
an amputation of the lower limbs is performed somewhere in the world as a result 
of diabetes7. 
The development of diabetic foot includes a multifactorial etiology; neuropathic, 
vascular and infectious (immunopathy), which because of an external or internal 
trauma, develop a foot injury. The main cause of ulcers is diabetic polyneuropathy 
due to the risk posed by the loss of sensitivity to the same trauma. Moreover, 
there are other etiological factors that increase the risk of foot ulcers, such as 
structural deformities, limited joint mobility and peripheral vascular disease8.  
G. March 
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Fig. 2.1 Algorithms of food ulceration in diabetic patients. 
 
2.1  DIABETIC FOOT INFECTION   
The presence of infection is an aggravating factor of these injuries but usually not 
the cause of the injury, except for trauma injuries9. Not all the diabetic foot ulcers 
are infected, but when the infection appears both the member and, sometimes, 
the patient's life are endangered.  
It is considered that the chronic wound is infected when observed local ischemia, 
abnormal color, smell foul, friable granulation tissue and/or presence of an 
intense pain not justifiable10.  
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It is accepted as clinical criteria the purulent infection or, at least, two signs or 
symptoms of inflammation (heat, redness, tumor pain and induration). Also, the 
presence of friable tissue, the cavitation under the surface of the wound and the 
foul odor suggest the presence of infection. General symptoms of infection are 
usually absent, but if they appear, they are suggesting the presence of a serious 
infection11.  
Diabetic foot infections affect bone and soft tissue causing necrotizing infections 
and osteomyelitis. Osteomyelitis is the septic complication most common in the 
diabetic foot syndrome. It is estimated that between 50% and 60% of infections 
in diabetic foot ulcers occur with bone infection, and of these, 10% to 30% require 
amputation12.  
The triggering cause of amputation in diabetic foot is infection more than 
ischemia, causing 90% of them, especially for a delayed diagnosis and treatment. 
 
2.2  DIAGNOSIS OF BONE INFECTION   
The main complication of acute episode is, undoubtedly, infection and, in many 
cases, the septic episodes worsen by a delayed diagnosis. One of the main 
challenges offered by the treatment of osteomyelitis in the diabetic foot is the 
difficulty of its diagnosis, especially when it comes to chronic OM. 
When bone infection is associated with a septic process of soft tissue that 
manifests itself with a picture of acute oozing, swelling, erythema and smelly, the 
diagnosis of infection is easier, although the treatment is more complex and the 
prognosis uncertain12.  However, when the bone infection occurs in patients with 
longstanding neuropathic ulcers that do not present any symptoms, diagnosis is 
more complex and the therapeutic action is delayed.  
Early diagnosis of osteomyelitis still remains a problem and a difficult challenge. 
There is so much controversy currently in determining tests for the diagnosis of 
diabetic foot bone infection. All authors agree that the histopathological study is 
the "gold standard", but is not generally used because obtaining bone tissue 
through a surgical debridement is aggressive and, therefore, involves risks for the 
patient13.  
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Imaging studies may be useful to define more clearly the deep purulent 
collections in soft tissue and are usually required to detect pathological signs of 
the bone. However, conventional radiology has a very low specificity and 
sensitivity and does not provides data for the early detection of bone infection in 
the first two weeks14.  
Meanwhile, most authors claim that are more accurate the studies with 
radioisotopes, PET (Positron Emission Proton) or MRI (Magnetic Resonance 
Imaging) but they are very expensive, take too long to make an early diagnosis 
and are not usually available in all clinics15-17.  
The diagnosis of OM should be fast because an infection in a diabetic patient can 
progress in hours and if not diagnosed in time, can reach to minor or severe 
amputations18. That is why the diagnosis should be primarily clinical, depending 
on the presence of local and systemic signs and symptoms of patients with 
diabetic ulcers. However, most of these patients have neuropathy and do not 
have any sensitivity to pain. 
This is why new methods which are non-invasive and technically easy have been 
proposed: the study of acute phase reactants, which rise in presence of infection 
and inflammation. They are considered, therefore, useful markers for the 
diagnosis and monitoring of OM. 
As laboratory tests to establish a diagnosis of infection we can use the leukocyte 
count, erythrocyte sedimentation rate and C-reactive protein (the last one is 
considered more sensitive than ESR for the diagnosis of OM19).  
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3. ACUTE REACTIVE PROTEIN  
Acute phase reactants are proteins markers which elevate during an acute or 
chronic infectious process, enabling their quantification and detection by blood 
tests. So, the infection acts as a powerful stimulus in the increase of these 
reactants; bacterial infections present stronger stimuli than parasitic or viral 
infections. The fact that some acute phase reactants increase in a higher 
proportion in some infections is helpful for us to know the prognosis and also to 
evaluate the effectiveness or not of the treatment used, even if it does not give 
information on the possible etiology.  
This acute phase reaction is characterized by a decrease or increase in the 
synthesis of transport proteins produced by the liver. Are called acute phase 
negative proteins (albumin and prealbumin) and positive proteins (CRP, 
complement C3 and fibrinogen) respectively. This phenomenon is induced by 
cytokines or interleukins generated where the damaged tissue is, mainly by 
macrophages and monocytes.  
 
 
Fig. 3.2 Increase of acute phase reactants during an inflammation process.20 
 
The functions of acute phase proteins include: opsonize, fix minerals, inhibit 
protease, increase blood clotting, remove foreign material and 
immunomodulation. 
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Even though CRP is still not an antibody, works as if it was for the abitily to join 
to bacteria through phosphorylcholine, a common constituent of microbial 
membranes. In addition to the binding capacity and opsonitzation of bacteria, 
CRP can activate the complement cascade through the alternate route. 
Besides, ESR is not an acute phase protein but it has been determined that the 
increase of fibrinogen is frequently associated with ESR increases and has also 
been demonstrated the presence of an inhibitory effect from serum albumin21.  
Some clinical episodes are clearly bacterial and do not require special efforts for 
its correct diagnosis but, sometimes, the clinic is masked by the associated 
diseases that present patients with diabetic foot and we have to rely on laboratory 
tests to evaluate erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), 
white blood cells and differential count and the microbiological cultures. However, 
none of nonspecific laboratory tests (ESR, CRP and white blood cells) may affirm 
or discard safely the diagnosis of an infectious disease such as osteomyelitis22.  
The acute phase reactants are a heterogeneous group of proteins that are 
synthesized in the liver and their amount increase rapidly in the presence of 
inflammation and tissue necrosis and in response to cytokine stimulation. They 
include coagulation proteins such as fibrinogen and prothrombin; transport 
proteins such as haptoglobin, transferrin and ceruloplasmin; components of the 
complement such as C3 and C4; protease inhibitors and various proteins such 
as albumin, fibronectin, C-reactive protein and amyloid A protein. 
The most frequently used acute phase reactants in clinical are erythrocyte 
sedimentation rate (ESR) and C-reactive protein (CRP). CRP levels reflect 
changes in inflammatory activity more quickly than the ESR, thus probably CRP 
is a good test for assessing early stages of inflammation. However, ESR only 
takes an hour to work and is technically simple whereas the determination of CRP 
has greater technical complexity. ESR may be elevated even in the absence of 
disease, may increase with age, in presence of anemia and generally in females 
is higher than males23.  
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Fig. 3.3 Alterations in some acute phase reactants following tissue injury24. 
(Note that CRP rise the highest and the fastest) 
 
Among the acute phase reactive proteins it can be found25:  
Proteins that the concentration of which increases by 50% over the basal level:  
- Ceruloplasmin   
- Third component of complement (C3)  
- 4th component of complement C4 
Proteins that the concentration of which increases from two to three times over 
the basal level:  
- AlF 1 antitrypsin  
- AlF 1 acid glycoprotein   
- AlF 1 antiquimiotripsina  
- Haptoglobin  
- Fibrinogen  
Proteins that the concentrations of which can increase 100 to 1000 times over 
the basal level:  
- C-reactive protein  
- SAA protein (serum component A from amyloid)  
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3.1  C REACTIVE PROTEIN (CRP)  
Among the acute phase reactants, CRP is the most widely used due to the 
features that presents by its high sensitivity and its kinetics of rapid evolution. 
Along with ESR, are the most used to detect and monitor acute phase responses. 
CRP was discovered in 1930 by William Tillet and Thomas Francis in the 
Rockefeller Institute and its name is due to the ability to precipitate C 
polysaccharide from Streptococcus pneumoniae. It consists of five identical 
subunits not glycosylated, covalently associated in a ring configuration with a 
cyclic pentameric symmetry26. 
It is an acute phase protein which, in the presence of Ca+2 ions, reacts with 
polysaccharide C (substance C is increased) of the pneumococcal cell wall 
(rough way) and causes precipitation, migrating with beta globulin fraction from 
serum in the electrophoresis. It stimulates phagocytosis. 
It has also been shown that activates the classical pathway of complement, it is 
set to T lymphocytes and inhibits clot retraction and platelet aggregation. It may 
constitute a mechanism of protection phylogenetically old and non specific. Acts 
as opsonin, interacting with lymphocytes and thrombocytes. 
Presents a significant homology with IgG; has a similar peptide sequence 
although it is antigenically differents, suggesting a common ancestral origin.  
It belongs to the proportion of beta globulins, approximate molecular weight of 
120,000 daltons, and its concentration tends to keep correlation with erythrocyte 
sedimentation rate, increases in most inflammatory and neoplastic diseases and 
it is detected in serum (increases CRP test). It is relatively thermostable, probably 
produced in the liver in response to biochemical signals that provide from the 
damaged or dead cells and is inactivated adding oxalate or citrate27. 
The concentration of this protein is very low in normal conditions, increases 
rapidly due to an acute inflammatory reaction, so abnormal concentrations can 
be detected within few hours of the start of this reaction. The concentration 
achieved by these proteins reflects the intensity of the underlying inflammatory 
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process. During very intense inflammatory reactions, it can quickly reach a 
concentration thousand times higher than the basal and in a quickly way28.  
It is also particularly effective in monitoring patient response to antibiotic 
treatment. It is more sensitive than ESR to evaluate the response to treatment. 
CRP is selectively deposited at the place of inflammation and can be degraded 
in fragments by neutrophil proteinase in the same place.  
The production of CRP may be affected by the products of fibroblasts, which are 
activated in combination with dexamethasone and it is also affected by heavy 
metals (cadmium, mercury, lead, copper, zinc, nickel).  
CRP, orosomucoide, leukocytes and ESR have a value on early diagnosis. 
PMN-elastase, alpha 1 antritripsina, ferroxidasa and haptoglonina and ESR are 
markers for a delayed use29.  
CRP shows a considerable rise in acute bacterial infections, while it is moderate 
or absent in viral infections. This determines its use for the detection of a hidden 
infection; to demonstrate the presence of a bacterial infection, especially when 
the microbiological diagnosis is difficult or when the obtention of the result is 
delayed; and to monitor drug therapy30.  
CRP is an important factor within the elements of the acute phase response due 
to the quickly increase of its concentration in a variety of inflammatory or tissue 
damage stadiums.  
It is a marker of inflammation, sensitive but not specific, which clearly increases 
after any type of inflammatory stimulus. C-reactive protein levels rise since the 6-
12 hours of the beginning of the inflammatory process and normalize in the 
absence of complications in two days. If the infection is not controlled, the levels 
remain high. It may be useful, therefore, as a marker of bacterial infection and to 
monitore therapeutic response. 
In healthy persons, CRP levels in plasma are usually less than 1mg/L, less than 
3mg/L in 90% of cases and less than 10mg/L in 96%. A normal CRP reflects the 
absence of an inflammatory process, an inflammation of less than 12 hours of 
evolution or a few inflammatory processes that do not elevate its values22. 
G. March 
 
18 
 
However, CRP has a high diagnostic value because, when compared to other 
markers of inflammation, it is elevated in all determinations where, for example, 
the ESR is abnormally high. ESR increases when there is an absence of 
inflammation, when there is an anemia due to a decrease of erythrocytes, during 
pregnancy due to the increase of fibrinogen and in necrosis due to the loss of 
albumin and the relative increase of the globulins; while the CRP has not a 
variable range between normal and abnormal concentration and is not influenced 
by anemia or others alterations in serum proteins31.  
At the same time, CRP has shown great utility when monitoring patients in order 
to know the effectiveness of treatment once the diagnosis of infection is done. 
The serum levels of CRP decrease rapidly when antibiotic treatment is right, 
keeping high when the treatment is ineffective32. 
 
3.2  ERITRHOCYTE SEDIMENTATION RATE (ESR)   
It is a routine test which measures the speed of red blood cells contained when 
a blood sample is precipitated to the bottom of a milimetred pipette. Under normal 
conditions, during the first hour, the precipitated volume is maximum 15mm for 
men and 20mm for women.  
The increase of ESR primarily reflects fibrinogen level and, to a lesser extent, the 
level of other acute reactive proteins. The increase of these very asymmetrical 
molecule proteins, promotes the breakdown of red blood cells forming piles of 
coins, which increase their weight without increasing proportionately its surface 
and settle faster. 
The elevation of the ESR for an inflammatory process is completely nonspecific 
and independent of the etiology of it. ESR is also less sensitive to the speed of 
response to a correct treatment33. 
The ESR, same way as CRP, is a nonspecific inflammatory marker that may be 
useful in the diagnosis of a bacterial infection. A disadvantage compared to CRP 
is that its rise in relation to inflammatory episodes is slow, both at the time of the 
debut and during the referral process and also when monitoring therapeutic 
response. Moreover, their values vary according to age, sex of the patient and 
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depend on series of reactions related to red blood cells, fibrinogen, lipids and 
immunoglobulins.  
Pathological values are considered when are upper than 25-30mm during the first 
hour34.  
The sedimentation rate mainly reflects the modifications of plasma proteins and 
those often accompany most acute and chronic infections, tumors and 
degenerative diseases.  
ESR is a nonspecific response to tissue deterioration and indicates the presence 
of disease, although it does not calibrate the severity of this31.  
The increase of erythrocyte sedimentation rate is characterized by infections. It 
is explained by the increase of fibrinogen and other acute phase reactants, which 
are large and asymmetric molecules that cause a sink effect of repulsive forces 
between blood cells red.  
 
3.3  ALBUMIN 
It is a plasmatic protein and its quantification is clinically useful.  
It is the most abundant protein in blood plasma, with a concentration between 35-
52g/L. It covers up to two thirds of total plasma protein content.  
Unlike the total protein, albumin reports the value of all globulins, with a 
combination of other fractions which can increase individually in severe 
conditions35. 
Its half-life in plasma is about 20 days. It catabolitzes in various tissues. Albumin 
is increased during infections, trauma and surgical operations. 
The main functions are maintaining the pressure plasma, using as storage of 
amino acids and transporting different ligands. Among the substances which are 
transported by albumin there are: hormones (thyroxine, estrogen), fatty acids, 
bilirubin, penicillin, cortisol, cumadina, calcium and magnesium.  
The main changes of plasma albumin are hyperalbuminemia, hypoalbuminemia 
and analbuminemia.  
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The hiperalbuminemia may be an artifact, for example, consequence of an 
excessive venous blood ecstasy during the extraction process, or an excessive 
parenteral infusion of albumin or a real effect on dehydration. 
The hypoalbuminemia may be physiological or pathological. The physiological 
can be because of the posture or pregnancy. With an upright posture, albumin 
increases its concentration whereas in pregnancy the concentration is reduced. 
When is pathological it may decrease due to a decline in its synthesis, an 
increase of catabolism, a reduced absortion of intestinal amino acids, an increase 
of distribution volume or an increase of the losses. Several diseases produce a 
decrease in albumin synthesis, such as malnutrition and liver processes36. 
After a trauma or a sepsis, occurs an increase in the permeability of the blood 
that leads to a redistribution of albumin, although in these situations there is also 
an increased catabolism. 
The increase in the proteic losses can be produced by urinary tract (nephrotic 
syndrome, glomerulonephritis, diabetes...) by feces (a protein losing enteropathy) 
or by the skin (burns). 
The measure of the concentration of albumin is a useful nutritional marker when 
monitoring during a long-term (several weeks or months) patients who receive 
nutritional support. However, its measure is also useful as a liver function 
parameter; (it is usually normal in episodes of acute hepatitis and decreased in 
chronic hepatitis)37.  
 
3.4  LEUKOCYTOSIS  
Is one of the most characteristic abnormalities of infectious diseases. Under 
normal conditions they are found between 4,000-10,000 leukocytes per mm3 of 
blood, in presence of infection they can reach up to 20,000 or 30,00028.  
The leucocytary formula consists in the determination of the percentage of each 
type of leukocytes - neutrophils, basophils, eosinophils, lymphocytes and 
monocytes - in relation to the total. This data can be very important in the 
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diagnosis of many infectious diseases in which the concentration of certain types 
of white blood cells increases significantly in relation to others.  
In general, leukocytosis is a very variable element and the relation between 
hyperleukocytosis and clinical signs of infection is not found in 60% of cases, 
giving many false positives38. 
 
Table I  
Analitical Data  
Normal Values:  
-Leukocytes (4-10, 5) 10 (9)/L  
-Neutrophils (2-7, 5) V.N. absolut  
-Lymphocytes (1, 2-4, 5) V.N. absolut 
-ESR (1-30) mm  
-CRP (<6mg/dl)  
-Albumin (3, 5 – 5,2g/dl)  
-Total protein (6-8g/dl)  
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4. OBJECTIVES 
4.1  GENERAL OBJECTIVE  
To assess the effectiveness of CRP in the diagnosis of osteomyelitis in diabetic 
foot patients.  
 
4.2  SPECIFIC OBJECTIVES  
 To validate if albumin, leukocytes and ESR are also useful parameters in 
the diagnosis of OM in diabetic foot.  
 To precise which others parameters of the blood test are altered in 
presence of OM, besides the acute phase reactants.  
 To analyze the characteristics more frequently found in OM patients.  
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5. MATERIAL AND METHODS   
Medical records collected in the database of Diabetic Foot Unit (UFPD) from 
Hospital de Bellvitge are randomly reviewed. Only patients who were attended at 
Emergency Unit diagnosed with osteomyelitis in the period between September 
2013 and April 2015 are included in the study.  
Records of diabetic patients hospitalized or treated in outpatient UFPD from 
internal medicine with diagnosis of <<osteitis>>, <<soft tissue infection>> or 
<<lower limbs cellulitis>> are obtained. Diagnosis of osteomyelitis is considered 
by the histopathological test.  
Those patients with no report of CRP, complete blood count and with no medical 
story in the period of analysis are excluded.  
 
Inclusion criteria  
- Diabetic patients who were attended at Emergency Unit with foot infection. 
- Diabetic patients from UFPD from Hospital de Bellvitge who were attended 
at Emergency Unit. 
- Patients from UFPD from Hospital de Bellvitge diagnosed with OM, osteitis 
or soft tissue infection and admitted to Hospital de Bellvitge. 
- With blood test before treatment. 
- CRP and complete blood test report. 
 
Exclusion criteria  
- Patients who do not have any blood test at the beginning of treatment. 
- CRP value was not reported in blood test. 
- Blood test after the antibiotic treatment. 
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5.1  ACTING PROCESS   
30 patients from the Diabetic Foot Unit of Hospital de Bellvitge are included in the 
study. They presented an episode of osteomyelitis and attended Urgency Unit in 
a period between 3th September 2013 and 3th April 2015.  
First, the medical records of the selected patients are accessed, looking for the 
blood analysis and subsequents clinical notes. 
Once achieved all analytical tests from patients, a statistical study of all the 
factors that are usually required in a case of OM is done. The aim of this study is 
to know if CRP is a valid method to diagnosticate OM and also if there is another 
factor, among those mentioned, which is also altered in most patients.  
A measurement of the following parameters is done:  
1- CRP  
2- ALBUMIN 
3- LEUKOCYTES   
4- COMPLETE BLOOD COUNT (CBC)   
The ESR has not been studied because in the analytical profile of the studied 
patients is not required.  
All 4 variables are measured and observed in each patient because bone 
infection is a sufficiently important process for do not eliminate all the 
complementary elements that we have available for its detection and control. 
Later, a monitoring of the clinical courses of patients is done. The purpose of this 
is to obtain more results and relationships with other co-morbidities which are 
associated with DM and, therefore, make a broader discussion and obtain more 
accurate results.   
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5.1.1 Variables to consider  
General  
- Age 
- Sex  
- Smoking   
- Nephropathy   
- Retinopathy  
- Previous amputations 
- Other associated complications  
 
From surgery 
- Surgical technique used   
 
Analytical variables 
- CRP: values pre and post surgical (comparison)  
- Complete blood count pre-surgical  
- Protein levels pre-surgical  
 
5.1.2 Statistical analysis  
All these data series are collected from each patient in a file. Subsequently, this 
file is included in a database which will help us to analyze the obtained data.  
A descriptive analysis is performed for the variables of the study. This consists in 
obtaining mesures of central tendency and dispersion for quantitative variables, 
using for the averages +/- their standard deviation.  
All statistical analysis are performed using Microsoft Office Excel 2013.  
From here, it is intended to reach the above objectives and to be able to establish 
a later discussion about if acute phase reactants are useful or not to detect and 
confirm the presence of OM.  
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6. RESULTS  
Once the results are obtained, we observe which of the matching parameters are 
altered in between all patients.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6.4 Results of blood test of all diabetic foot patients diagnosed with OM. 
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In figure 4, all factors are captured to observe which are altered. To achieve this, 
0% represents the minimum normal level and 100% the maximum, this way all 
factors are in the same scale and can be compared on the same chart. If the 
round red is located outside the minimum or maximum, the average of the factor 
in question is altered.  
The factors that are altered in the majority of the studied patients during a bone 
infection are clearly visible in this figure.  
Creatinine, glucose and gamma-glutamyltransferase are above their standard 
values. The fact that glucose displays high in diabetic patients is logical. Just as 
creatitina also means that these patients often present a nephropathy. The 
gamma-glutamyltransferase is used to detect diseases of the liver so, its high 
levels are not useful for this study.  
At the same time, alkaline phosphatase and CRP are found altered. It will be 
discussed later.  
From complete blood count, not all factors are included because they are not 
requested in analytical profiles of all patients; however, from the requested 
parameters of the CBC of all patients, erythrocytes, hemoglobin and neutrophils 
are altered. Leukocytes are slightly higher. It will also be discussed with more 
detail in the following sections.  
Albumin is also slightly altered. 
  
6.1  ANALYTICAL RESULTS   
According to the histopathological results, the levels of CRP and the complete 
blood count are compared. It is proved that they have an important role in front 
of an infectious process. In the same way, albumin and alkaline phosphatase are 
also specifically studied because they have shown altered and it could also 
influence the diagnosis of OM.   
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6.1.1. C reactive protein  
It is observed that patients with OM have a CRP much higher than the ones with 
no marrow affectation. 
 
 
Fig. 6.1.1.5 CRP results of the studied patients. 
 
In the population of the 30 studied patients, CRP serum levels are in all patients 
above the normal range. 
The CRP of healthy patients should be between 0 and 5 mg/L whereas the 
average of CRP in our patients is 69,81mg/L. This indicates that, in presence of 
an infection, the protein is altered and its blood levels soar. The hypotesis of this 
thesis is resolved in the above figure.  
 
6.1.2. Albumin  
The albumin is also studied because it has been altered in the studied patients. 
In healthy patients this protein has a basal level between 35 and 53 g/L while in 
the studied patients this protein is below levels, with an average of 35 g/L (the 
minimum value of the protein).  
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Fig. 6.1.2.1 Albumin results of the studied patients. 
 
According to the bibliographical research done, albumin is directly linked to ESR. 
In the studied patients from UFPD, the ESR has not been assessed because it is 
not regularly asked in the analytical profile of patients suspected to have OM as 
CRP is considered to be more important.  
 
6.1.3. Alkaline phosphatase   
Alkaline phosphatase is also included in a specific section as an important 
alteration can be observed from the statistical figure of all factors (Fig 6-4). In 
healthy patients, this protein has a basal level between 0 and 2,15 µKat/L, while 
the average in the studied patients is 11 µKat/L. However, when the individual 
study is performed, the reason for the alteration in the average value is easily 
understandable. From the 30 studied patients, two of them have very high levels 
of this protein (above 120 µKat/L), which heavily impacts the average values from 
the study sample. Therefore, alkaline phosphatase can not be used as a reliable 
marker when diagnosing OM.  
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Fig. 6.1.3.2 Alkaline phosphatase results of the studied patients. 
 
6.1.4. Blood count  
Among the studied factors from the CBC: leukocytes, neutrophils, erythrocytes 
and hemoglobin are shown altered. For this reason, they are analyzed 
individually.  
 
Leukocytes   
In the general graph, leukocytes are slightly altered but once the statistical study 
is done, it is observed that in some patients are indeed very high but in the 
majority are within the normal ranges. Therefore, leukocytes are not a 
determining factor for the diagnosis of OM.  
Leukocytes are between 3,9 and 9,5x109/L in healthy patients, the average in the 
30 studied patients is 9,07x109/L.  
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Fig. 6.1.4.3 Leukocytes results of the studied patients. 
 
Neutrophils  
Neutrophils, same way as leukocytes, showed a slight alteration in the general 
graph because there is a lot of variability between patients. Some patients have 
levels above the maximum normal values, while there are patients whose levels 
are below the minimum. The majority of the studied patients present neutrophils 
within normal ranges, and therefore, it is not a valuable parameter when 
diagnosing OM. In healthy patients the levels of neutrophils are between 1,5 and 
5,7x109/L while in these patients the average is 6,43x109/L.  
 
 
Fig. 6.1.4.4 Neutrophils results of the studied patients. 
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Erythrocytes  
In the individual graph it is shown how erythrocytes, which are altered in the graph 
of all factors, are in almost all patients below the minimum range of normality. 
This fact has sufficient validity to indicate that studied patients with osteomyelitis 
present very low values of red blood cells. A relationship between bone infection 
and low concentration of erythrocytes could be established. 
Erythrocytes levels in healthy patients are between 4,3 and 5,6x1012/L while in 
the studied patients, the average of erythrocytes is 3,74x1012/L.  
 
 
Fig. 6.1.4.5 Erythrocytes results of the studied patients. 
 
Hemoglobin  
Simultaneously, hemoglobin is shown altered in the general graph. In the 
individual study, abnormally low levels in almost all patients can be observed. As 
well as with erythrocytes, it could be affirmed that there is an existing relationship 
between diagnosis of infection and hemoglobin concentration in blood.  
The average of hemoglobin in the studied patients is 107g/L while parameters in 
healthy patients are between 130 and 165g/L.  
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Fig. 6.1.4.6 Hemoglobin results of the studied patients. 
 
Of these four results of the CBC that showed altered in the general chart, it can 
be concluded that, when there is a bone infection as OM, the only parameters 
from the CBC that seem to be altered and have significant detection value are 
erythrocytes and hemoglobin. These two factors are below their minimum when 
the body of a diabetic patient has a bone infection.    
 
6.2  SURGICAL PROCEDURES RESULTS  
56,7% of the patients have undergone surgical amputation as a treatment for the 
diabetic foot infection. The surgical procedures performed were: digital 
amputation (55,5%), transmetatarsal amputation (22,2%), infracondylar 
amputation (11,1%)  and arthrodesis (5,6%) (detailed information of all patients 
can be found in Annex).  
 
6.3  GENERAL RESULTS    
There is a predominance of male over female from suffering osteomyelitis in the 
studied patients (4:1). As well as the appearance of osteomyelitis is more 
common after age of 50, with few cases before age of 50.  
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Fig. 6.3.7 Age and sex group of the studied patients. 
 
The main comorbidity reported has been smoking (53,33% of the patients), 
followed by nephropathy (33,33% of the studied sample).  
Dyslipidemia was presented only in 20% of the patients. Other comorbidities 
reported were: previous history of amputation, retinopathy, heart disease and 
hypertension. (detailed information of all patients can be found in Annex).  
 
 
Fig. 6.3.8 Associated comorbidities of the studied patients. 
 
Finally, a follow-up of three of the total studied patients is included. The aim of 
this, is to compare the levels of CRP when OM is diagnosed with the levels when 
patients are already with pharmacological or surgical treatment. This will help us 
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to know if the levels of this proteins respond favorably to drug administration and 
surgery, as found bibliographically.  
 
 
Fig. 6.3.9 CRP levels before and after antibiotic teraphy 
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7. DISCUSSION  
Although the number of studied cases has been reduced to obtain a statistically 
significant difference, the tendency to higher levels of CRP in all patients with OM 
report compared to those without bone infection has been demonstrated. This 
finding is similar to other series already reported, indicating that CRP is an 
important factor in the diagnosis of osteomyelitis.  
However, further studies with significant sample of patients to affirm with greater 
validity the hypothesis should be reported. This thesis is just an initial study where 
the trend of CRP in front of an episode of osteomyelitis is observed, but more 
detailed investigation on the observed relationships should be carried out.  
It is also important to note that CRP values decrease drastically once the infection 
is treated, both pharmacologically and surgically, which helps us to monitor the 
evolution of OM and the effectiveness of the treatment given.  
On the other hand, the undertaken research has not been able to assess the 
diagnostic value of ESR because it was not requested in the analytical profiles of 
the studied patients, which falls beyond the scope of our work. 
Albumin and leukocytes have shown to present a lot of variability between 
patients. Therefore, neither of these proteins have demonstrated their 
effectiveness when diagnosing osteomyelitis.  
From the complete blood count, erythrocytes and hemoglobin are below normal 
levels in almost all patients with OM. This could be relevant when proposing 
further studies that specifically evaluate these two factors as they seem to have 
a close relationship with the appearance of OM.   
Patients with diabetic foot have severe cardiovascular risk factors such as 
smoking, excess weight and presence of complications associated with diabetes 
(retinopathy, nephropathy, hypertension and amputation). 
It has been observed that 20% of patients refer to have dyslipidemia or are 
treated with a statin. A remarkable feature is the antecedent of previous 
amputation in a considerable proportion of the population. The history of foot 
ulcers and amputation significantly increases the likelihood of subsequent ulcers. 
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These whole series of complications, both micro and macrovascular as well as 
previous episodes of amputation reflect the serious systemic deteriorations of the 
selected population, so there is a worse prognosis on function and morbidity. 
About epidemiology, there is higher incidence of suffering osteomielitis after the 
age of 50 with higher prevalence in males.  
Due to the individual and social impact that diabetic foot causes, it is required to 
implement prevention programs and take better care of risk patients in order to 
avoid adopting extreme measures in late situations. These educational measures 
should be directed to patients, families and doctors (both first contact and 
specialists of different areas that are in contact with diabetic patients).  
To sum up, Magnetic Resonance Imaging (MRI) is the study that has shown to 
have greater utility in the noninvasive development of osteomyelitis in the diabetic 
foot. However, its low availability in our environment is a limiting factor and that’s 
why other indirect markers have been looked for. C-reactive protein may be a 
support diagnosis when osteomyelitis is suspected, but it has to be considered 
or interpreted in the clinical context of the patient and in conjunction with 
radiological studies.  
If acting on the diagnosis of almost all diabetic foot patients who present bone 
infection was possible, the decrease in the prevalence of amputations would be 
a reality. This would improve the life quality of diabetics.  
Currently, it is just an ideal instead of the goal of many Medical teams. To achieve 
this, it is necessary to raise awareness on this health problem and, therefore, 
keep working to implement widely agreed guidelines for early and accurate 
diagnosis.   
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8. CONCLUSIONS  
In the analyzed population there is a delay in the diagnosis of osteomyelitis due 
to the difficulties that diabetic foot infection involves.  
C-reactive protein has shown to have high diagnostic value for OM.  
The ESR has not been evaluated in the studied patients because it is not 
requested in the analytical profile of the studied Unit, which implies that it is not 
worth considering when diagnosing OM.  
Albumin and leukocytes are not value parameters to diagnose OM. From CBC, 
hemoglobin and erythrocytes appear to be related to the onset of OM.  
OM appears more frequently in male and after the age of 50. Smoking is the main 
comorbidity of these patients followed by nephropathy.  
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1. FACTORS OF THE BLOOD TEST  
Factor Urea Creatinine 
Glomerular 
Filtration Rate 
1 6,2 66 90 
2 8 60 90 
3 3,6 56 90 
4 4,9 57 90 
5 4,2 59 90 
6 4,1 65 90 
7 7,9 129 52 
8 6,6 90 74 
9 11,5 123 74 
10 6,4 94 89 
11 7,1 86 76 
12 6,7 130 38 
13 5 75 90 
14 7,5 146 47 
15 9,3 137 47 
16 4,9 106 66 
17 3,6 56 90 
18 13,1 510 10 
19 7,2 138 49 
20 18,1 320 16 
21 7,5 102  
22 19 282 20 
23 19,7 121 51 
24 6,6 88 80 
25 7 99 69 
26 7,5 119  
27 6 73 90 
28 22,1 625 8 
29 17 153 39 
30 2,9 72 90 
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Factor 
Sodium Ion; 
c.subst. 
Potassium Ion; 
c.subst. 
Glucose; 
c.subst. 
1 144 5,19 5,2 
2 139 5,32 9,2 
3 144 5,28 6,6 
4 142 5,16 5,8 
5 136 4,69 6,9 
6 134 4,85 7,4 
7 142 5,1 20,2 
8 142 4,16 8,6 
9 138 4,96 5,9 
10 133 4,5 10,6 
11 137 6,19 4,8 
12 141 3,94 3,3 
13 139 4,48 7,2 
14 139 4,58 9,5 
15 132 4,5 17 
16 141 5,17 3,6 
17 144 5,28 6,6 
18 140 3,81 4,9 
19 142 5,4 5,4 
20 149 4,97 8,6 
21 136 4,12 16,8 
22 143 5,59 5 
23 138 4,12 11 
24 132  4,2 
25 122  6 
26 142 4,56 7 
27 137 4,66 11,5 
28 136 4,34 5,2 
29 137 4,87 2,2 
30 137 5,3 5,8 
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Factor 
Alanine-
aminotransferase
; c.cat. 
Albumin; 
c.massa (CRM 
470) 
Gamma-
glutamyltransferase
; c.cat.  
1 0,23 38 0,52 
2 0,41 34 1,46 
3 0,22 42 1,29 
4 0,4 45 0,3 
5 0,51 41 1,42 
6 1,13 45 9,98 
7 0,17 40 0,62 
8 0,08 37 0,24 
9 0,08 38 0,24 
10 0,31 37 0,89 
11 0,11 37 0,55 
12 0,11 25 0,35 
13 0,25 41 0,76 
14 0,38 28 0,73 
15 0,38 29 0,74 
16 0,08 30 0,16 
17 0,22 42 1,29 
18 0,63 36 0,95 
19 0,61 31 0,34 
20 0,21 40 0,47 
21 0,36 34  
22 0,23 36 0,74 
23 1,82 35 3,59 
24 0,44 33  
25 1,12 31 1,99 
26 0,4 36  
27 0,33 38 0,38 
28 0,12 30 0,55 
29 0,38 25 5,23 
30 0,2 24 0,65 
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Factor 
Alkaline 
Phosphatase; 
c.cat.  
C Reactive 
Protein; c.massa 
(CRM 470)  
Erythrocytes 
c.nom 
1 1,98 67,2 3,89 
2 2,04 17,1 4,72 
3 1,13 23,7 4,15 
4 1,29 2,2 4,77 
5 1,2 60,5 3,79 
6 2,82 17,9 4,61 
7 1,5 27,5 2,97 
8 0,37 54,8 3,59 
9 0,37 88,1 3,2 
10 1,61 175,8 4,72 
11 1,79 25,2 2,98 
12 1,32 26,7 2,78 
13 1,66 40,1 4,47 
14 122 193,4 3,71 
15 122 252 4,3 
16 0,6 108,2 3,75 
17 1,13 23,7 4,15 
18 1,94 15,9 3,02 
19 1,25 61,7 3,94 
20 1,84 29,9 3,85 
21  193 3,7 
22 0,88 75,2 3,53 
23 1,62 67,2 3,53 
24  76,5 3,69 
25  53,1 3,35 
26  69,8 3,5 
27 1,31 10,7 4,56 
28 1,76 60 2,48 
29 8,75 109,4 3,45 
30 2,07 67,7 3,07 
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Factor 
Hemoglobin; 
c.massa 
Erythrocytes; 
fr.vol 
(hematòcrit)  
Erythrocytes; 
vol entílic (VCM)  
1 119 38,1 98 
2 118 37,8 80 
3 132 41,2 99 
4 144 44,4 93 
5 105 0,323 85 
6 144 0,436 95 
7 83 0,27 91 
8 82 0,257 71 
9 70 0,219 68 
10 134 0,401 85 
11 97 0,291 98 
12 82 0,25 90 
13 130 0,377 84 
14 108 31 84 
15 124 35,6 83 
16 104 32 85 
17 132 41,2 99 
18 90 0,282 94 
19 114 0,358 91 
20 110 0,318 83 
21 105 32 87 
22 104 0,323 91 
23 103 0,312 88 
24 107 0,319 87 
25 97 0,272 81 
26 100 30,8 87 
27 129 0,395 87 
28 77 0,236 95 
29 99 30,6 89 
30 81 26 85 
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Factor 
Hemoglobin; 
massa entilica 
(HCM) 
Hemoglobin; 
c.massa (CHCM) 
Erythrocyte 
volume; width 
relative 
distribution 
1 31 312 14,9 
2 25 312 15 
3 32 320 13,8 
4 30 324 12,5 
5 28 324 16,9 
6 31 329 16,1 
7 28 309 18 
8 23 318 24,3 
9 21 300 21 
10 28 334 17,8 
11 33 335 17,3 
12 30 330 17,8 
13 29 344 15,9 
14 29 348 12 
15 29 348 12,3 
16 28 325 13,1 
17 32 320 13,8 
18 30 318 20 
19 29 318 15,8 
20 29 345 18,1 
21 29 328 13,9 
22 29 320 16,9 
23 29 330 18,9 
24 29 335 16,2 
25 29 355 15,4 
26 28 325 13,2 
27 28 327 16,1 
28 31 328 17,1 
29 29 324 15,4 
30 26 312 14,7 
 
 
 
 
 
 
 
G. March 
 
52 
 
Factor Platelets c.nom 
Platelets; vol 
entilic (VPM) 
Leukocytes 
c.nom 
1 338 11,4 6,5 
2 420 11,4 11,3 
3 161 11,7 5,1 
4 195 10,2 7,4 
5 362 7,7 7,9 
6 134 10 7,2 
7 168 9,5 6,4 
8 378 7,8 6,5 
9 621 7,2 7,2 
10 348 10,6 15,5 
11 357 9,7 8,7 
12 96 8,6 2,3 
13 332 10,1 9,7 
14 334 9,3 8,7 
15 449 9,1 19,8 
16 304 11,5 9,1 
17 161 11,7 5,1 
18 165 7,8 5,5 
19 301 8,6 8 
20 260 8,7 12,4 
21 230 10,9 9 
22 244 10,5 10,1 
23 221 9,6 2,6 
24 376 8,4 10,9 
25 848 7,9 11,5 
26 276 10,9 11,7 
27 311 8,6 8,5 
28 159 7,9 4,2 
29 483 10,5 20,9 
30 581 10 12,3 
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Factor 
Neutrophils 
c.nom 
Lymphocytes 
c.nom 
Monocytes 
c.nom 
1 4,1 1,7 0,51 
2 5,9 4,1 0,69 
3 2,8 1,4 0,63 
4 3,9 2,5 0,8 
5 5,6 1,4 0,54 
6 5,3 1,2 0,5 
7 5,6 0,6 0,19 
8 4,4 1,5 0,47 
9 5,2 1,4 0,36 
10 11,6 2,1 1,5 
11 6,5 1,6 0,25 
12 1,4 0,7 0,07 
13 6,3 2,4 0,63 
14 6,3 1,2 1,02 
15 17,4 0,9 1,4 
16 6,4 1,6 0,86 
17 2,8 1,4 0,63 
18 3,6 1,2 0,42 
19 4,9 2,1 0,5 
20 8,8 2,3 0,91 
21 6,4 1,5 0,8 
22 7 1,6 0,76 
23 2,4 0,1 0,05 
24 8,1 1,4 1,18 
25 8,3 1,6 1,29 
26 8,6 1,9 1,06 
27 5,4 2,3 0,61 
28 2,6 0,8 0,47 
29 16,2 2,6 1,81 
30 9,2 2,2 0,83 
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Factor 
Eosinophils 
c.nom Basophils c.nom 
Tissue factor-
induced 
coagulation  
(prothrombin 
time; IRP 67/40) 
1 0,14 0,07 1,12 
2 0,52 0,08 1,52 
3 0,18 0,03 0,99 
4 0,16 0,04 1,01 
5 0,24 0,07 1,06 
6 0,09 0,06 1,06 
7 0 0 1,37 
8 0,1 0,08 1,12 
9 0,11 0,1 1,13 
10 0,14 0,09 1,03 
11 0,2 0,08 1,13 
12 0,05 0,05 1,34 
13 0,28 0,08 1,1 
14 0,13 0,1 1,3 
15 0,01 0,15 1,44 
16 0,2 0,05  
17 0,18 0,03 0,99 
18 0,23 0,05 1,01 
19 0,26 0,16 1,17 
20 0,39 0,07  
21 0,23 0,03  
22 0,65 0,13 1,2 
23 0,08 0 1,17 
24 0,16 0,12  
25 0,21 0,1  
26 0,12 0,06 1,08 
27 0,09 0,05 1,03 
28 0,2 0,07 1,06 
29 0,19 0,14 1,16 
30 0,08 0,05 1,14 
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2. OTHER FACTORS  
Patient Age Sex Comorbidities Smoke 
Previous 
Amputation 
1 70 M Smoke Yes  
2 73 M Smoke Yes  
3 65 M Cirrhosis   Yes 
4 63 M    
5 66 M Smoke Yes  
6 59 M Cirrhosis     
7 64 M HTA   Yes 
8 59 F Smoke, EPOC Yes Yes 
9 32 F   Yes 
10 38 M No AMC    
11 75 F Smoke Yes Yes 
12 54 M Smoke  Yes Yes 
13 60 M Smoke Yes  
14 55 M Smoke Yes Yes 
15 57 M Smoke  Yes Yes 
16 58 M Smoke, obesity  Yes  
17 80 F    
18 72 M HTA, DLP    
19 52 M Smoke, Alcohol  Yes Yes 
20 60 F HTA, DLP   
21 74 M 
Smoke, Obesity, HTA, 
Alcohol    
Yes  
22 65 M HTA, DLP, DBM    
23 60 M HTA, DLP, DM     
24 70 M Smoke Yes  
25 65 F Smoke Yes  
26 67 M    
27 80 M    
28 58 M Smoke Yes  
29 73 M    
30 71 M Smoke Yes  
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Patient Dyslipemia Nephropathy Retinopathy HTA 
Heart 
Disease 
1      
2      
3      
4      
5  Yes  Yes  
6    Yes  
7      
8 Yes   Yes Yes 
9 Yes   Yes  
10    Yes Yes 
11  Yes  Yes  
12   Yes   
13      
14 Yes Yes Yes Yes  
15  Yes   Yes 
16 Yes Yes  Yes  
17 Yes  Yes   
18  Yes Yes   
19 Yes   Yes  
20  Yes    
21     Yes 
22     Yes 
23   Yes   
24  Yes    
25      
26  Yes    
27      
28  Yes    
29      
30      
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Patient Diseases 
1 Amputation 1st ray  
2  
3 
Amputation distal phalanx 3º PD (2011), Amputation 1st PD (2014), Amputation 
2nd PD (2014), Amputation 4th & 5th fingers PD (2014) , Amputation TMT PD 
(12/2014)  
4  
5 
HTA & DLP, Nephropathy, Ischemic Sd. , Amputation 3rd finger MID (2012), 
Ulcer PD 
6 
HTA, anemia, Obesity, Amputation 2nd & 5th PD (2014), Ulcer 2nd & 5th 
fingers PD.  
7 
Polyneuropathy & Charcot Arth. , Arthrodesis bilat. (2010), Arthrodesis (2015), 
Infected Plantar ulcer (long evolution) 
8 
Neuropathy Ischemic Cardiopathy, HTA y DLP, Amputation 1st PD (2011), 
Amputation 3rd PD (2013), Surgical Debridement (2014)  
9 
HTA, DLP, Transmetatarsal amputation PE (2013), Arthroplasties, 
debridements, HAV, claw toes , Exostectomy calcaneus (2014) PE  
10 HTA & tachycardia, Amputation transmtt (2013)  
11 EPOC, HTA, Nephropathy, Amputation 3rd 4th PI & 2nd PD  
12 
Retinopathy (IQ), Vasculopathy perif., Amputation 1st PE (2003), Amputation 5º 
PD (2008), Debridement PE + exeresis 5th mtt 
13 Obesity  
14 
HTA, DLP, Nephropathy Retinopathy, AVC 06, Peyronie, Amputation 4th PD 
(2013), Amputation 2-3rd PD (2011)  
15 
Nephropathy, VHC , HBP, Ulcer intern malleoli + arthropathy, 18/7 Infracondilar 
amputation EIE x Charcot, Reamputation x bad evolution 
16 HTA, DLP, periferic neuroph. , Nephropathy, Plantar ulcer 5th mtt 
17 Retinopathy, DLP  
18 
Nephropathy, retinopathy, Infracondilar Amputation, Plantar ulcer (PE) CMTT 
3-4 
19 
HTA, DLP, IRC, Perif neuroph., Mieloma, Plantar ulcer D, OM phalanx 3º, 
Digital Amputation (15)  
20 Nephropathy, Artropathy associated, Bunionectomy + soft tissue OT 1st  
21 Cardiopathy,  ictus isq ACM , Intern Ulcer, Amputation 1st 
22 Hyperplasia prostate, periferic vasculopathy, edema 1st ray  
23 Retinopathy, Ulcer 5th mtt, Transmetatarsal Amputation 2014 PE   
24 Nephropathy 
25  
26 Nephropathy 
27  
28 Nephropathy 
29 Obesity  
30  
 
